As the global healthcare landscape shifts toward weight-loss treatments and chronic care, investors are weighing two giants. Should you invest in Novo Nordisk A\/S (NYSE:NVO) or Pfizer Inc.(NYSE:PFE) today? <\/p>\n
Novo Nordisk A\/S has built a dominant position in the diabetes market, while Pfizer offers a broad range of vaccines and medicines. They are now competing more directly as Pfizer expands into metabolic health. This comparison looks at their financials, risks, and valuations to determine which stock is the better choice for your portfolio. <\/p>\n
The case for Novo Nordisk A\/S <\/p>\n
Novo Nordisk A\/S focuses on serious chronic diseases, specifically diabetes and obesity. It operates a global business, marketing products in roughly 170 countries with a workforce of nearly 70,000 employees. The company maintains a specialized focus that distinguishes it from more diversified players among healthcare stocks<\/a>. It does not report any single customer accounting for more than 10% of total revenue. <\/p>\n In FY 2025, revenue reached about $46.5 billion, representing a growth rate of roughly 6.4% compared to the previous year. The company remains highly profitable, generating net income of approximately $15.4 billion for the same period. This resulted in a strong net margin of roughly 33%, which measures how much profit the company keeps for every dollar of sales. This trend of high profitability has been consistent over the last three fiscal years. <\/p>\n As of its December 2025 balance sheet, the company maintains a debt-to-equity ratio of roughly 0.7x. This metric, which compares total debt to the value of what shareholders own, suggests a manageable debt load. Its current ratio stands at approximately 0.8x, measuring the ability to cover short-term debts with short-term assets. In FY 2025, the company generated free cash flow of about $4.4 billion, which is the cash left over after paying for operations and equipment. <\/p>\n The case for Pfizer Inc. <\/p>\n Pfizer discovers and manufactures a vast array of medicines and vaccines used in roughly 200 countries. Its business is currently centered on building a massive presence in oncology and obesity through the acquisitions of Seagen and Metsera. The company deals with significant customer concentration, as its top 12 products accounted for about 65% of its total 2025 revenue. Its drug Eliquis is a major contributor, representing approximately 13% of its total annual sales. <\/p>\n In FY 2025, revenue reached around $62.6 billion, which was a slight decrease of roughly 1.6% from the prior year. Despite the revenue dip, the company reported net income of around $7.8 billion for the fiscal year. This performance resulted in a net margin of approximately 12.4%. While its total revenue is higher than that of its peers, Pfizer is currently managing a period of transition as it integrates new business units and adjusts to changing drug demands. <\/p>\n As of its December 2025 balance sheet, Pfizer carries a debt-to-equity ratio of roughly 0.8x. This level of total debt relative to shareholder equity is comparable to its industry peers. Its current ratio is approximately 1.2x, indicating a solid ability to meet short-term financial obligations. For FY 2025, the company produced around $9.1 billion in free cash flow, providing significant capital for dividends and further business development. <\/p>\n Risk profile comparison <\/p>\n Novo Nordisk A\/S faces significant risks from increasing competition in the obesity and diabetes drug markets. Regulatory bodies in various countries are also scrutinizing drug prices, which could impact the high net margin the company currently enjoys. Additionally, the company must successfully manage complex manufacturing and supply chains to meet the massive global demand for its injectable therapies. Any disruption in production could lead to immediate loss of market share to new entrants. <\/p>\n Pfizer is navigating a substantial revenue reduction through 2030 as several of its major products lose patent protection. It is also subject to intense pricing pressure from the Inflation Reduction Act, which allows the government to set prices for drugs like Eliquis and Ibrance. Furthermore, the company faces ongoing litigation regarding products like Depo-Provera and Chantix. It must also compete for market share in the vaccine space against rivals such as Moderna Inc (NASDAQ:MRNA). <\/p>\n Valuation comparison <\/p>\n Pfizer currently offers a lower entry point based on earnings and sales, while Novo Nordisk A\/S carries a higher valuation reflecting its superior net margin. <\/p>\n Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers. <\/p>\n The P\/S ratio<\/a> mentioned above measures the stock price relative to sales over the past twelve months. The Forward P\/E measures the current stock price against future earnings estimates. <\/p>\n Which stock would I buy in 2026? <\/p>\n Pfizer isn’t a hot growth stock, but it’s also one of the giants of the pharmaceutical industry. <\/p>\n The company had a post-COVID 19 letdown of sorts, as pandemic-related demand ebbed, but the business has been flexing its might this year. In its first quarter of this year, Pfizer beat Wall Street analysts’ expectations on sales and net income. That is partly because Pfizer has been buying growth — it recently acquired oncology specialist Seagen and posted 20% growth in that business’s products. <\/p>\n Pfizer is also allocating significant resources to new drug development, with 20 drug development starts scheduled for 2026 and eight data readouts expected, which report on the progress of treatments in development. After falling behind in the GLP-1 weight-loss drug market, Pfizer is also making strides toward becoming a competitor, with very positive Phase II (of III) trial results for an injectable GLP-1 reported earlier this year. <\/p>\n For the current fiscal year, Pfizer revenue is seen slumping to $62.2 billion mildly, though net income is seen rising $1.2 billion to $8.9 billion for the year. <\/p>\n Novo Nordisk has the blockbuster drugs Wegovy and Ozempic (the same drug marketed for different purposes), but faces investor doubts about its market position given a deal with the federal government to lower prices for the GLP-1s, the emergence of generic competitors, and the apparent advances by Eli Lilly & Co (NYSE:LLY) in developing weight loss drugs expected to be superior to Novo’s offerings. <\/p>\n Still, the introduction of the once-a-day Wegovy pill in the U.S. has been a resounding success, and the business has a patent on injectable Ozempic\/Wegovy till 2032, providing it some competitive moat. Still, Wall Street sees sales declining by about 3% in fiscal 2026, with net income contracting by 4% as pricing pressures erode margins slightly. Long-term, analysts expect the company to reverse the 2026 decline and start growing again as new products come online. <\/p>\n Both are pharma giants under some pressure this year. Pfizer’s value-style ratios and its improving net income this year make it the stock to choose compared to Novo Nordisk. <\/p>\n Should you buy stock in Novo Nordisk right now? <\/p>\n Before you buy stock in Novo Nordisk, consider this: <\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. <\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $365,910!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,418,530!* <\/p>\n Now, it’s worth noting Stock Advisor’s total average return is 930% \u2014 a market-crushing outperformance compared to 211% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. <\/p>\n See the 10 stocks \u00bb<\/a> <\/p>\n *Stock Advisor returns as of October 2, 2026. <\/p>\n Brendan Coffey<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Moderna, Novo Nordisk, and Pfizer. The Motley Fool has a disclosure policy<\/a>. <\/p>\n